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CLCN5 mutation Ser244Leu is associated with X-linked renal failure
without X-linked recessive hypophosphatemic rickets. This study demon-
strates that a missense mutation in the voltage gated chloride channel,
CLCN5, can cause X-linked renal failure without X-linked recessive
hypophosphatemic rickets. A large kindred (Family A), initially evaluated
in 1974 with an inherited syndrome characterized by hypercalciuria,
nephrocalcinosis, low molecular weight proteinuria, renal tubular acidosis,
and renal failure, was clinically re-evaluated and genetically characterized.
Medical histories, physical examinations, blood chemistries, and 24-hour
urine collections were obtained from 48 family members. Both female and
male family members exhibited hypercalciuria, nephrolithiasis, and low
molecular weight proteinuria. However, only men developed renal insuf-
ficiency, consistent with an X-linked recessive gene defect. Genetic linkage
located the disease locus on the proximal short arm of the X chromosome
(Xp11) where a voltage gated chloride channel gene, CLCN5, had
previously been mapped. DNA sequence of the CLCN5 gene demon-
strated a missense mutation (Ser244Leu) in affected family members. The
same missense mutation has previously been shown to cause X-linked
recessive hypophosphatemic rickets. No affected member of Family A had
evidence of chronic hypophosphatemia, clinically significant rickets, or
osteomalacia. We hypothesize that genetic background, environment, diet,
or an unidentified modifying gene may account for the differing pheno-
types resulting from this shared gene defect.
A three generation kindred was reported in 1974 [1] with a
syndrome characterized by nephrolithiasis, hypercalciuria,
nephrocalcinosis, proteinuria, variable renal tubular acidosis, and
renal failure. Hypercalciuria was postulated to cause the subse-
quent development of nephrocalcinosis, renal tubular acidosis,
and renal failure. Although this syndrome was originally called
hereditary renal tubular acidosis [1], renal acidification abnormal-
ities were not a consistent feature of the phenotype, and were
likely secondary to long-standing hypercalciuria and nephrocalci-
nosis. Further, longituditional observation showed that renal
failure developed only in men, suggesting an X-linked syndrome.
Three X-linked disorders, X-linked recessive nephrolithiasis
(XRN) [2–4], Dent’s disease [2, 5, 6], and X-linked recessive
hypophosphatemic rickets (XLRH) [2, 7, 8] share clinical features
with X-linked renal failure. A fourth X-linked disorder with
features similar to X-linked renal failure including low molecular
weight proteinuria, hypercalciuria, and nephrocalcinosis has re-
cently been described [9]. These four conditions have been shown
to be caused by mutations in a voltage-gated chloride channel,
CLCN5, which is located on chromosome Xp11 [2, 9]. To
determine if mutations in CLCN5 might also cause X-linked renal
failure in family A, we clinically characterized individuals from
Family A and mapped X-linked renal failure to Xp11. The
sequence of CLCN5 was determined and a missense mutation was
identified in all affected individuals. Surprisingly, the same
CLCN5 missense mutation has been demonstrated to cause
X-linked recessive hypophosphatemic rickets, which is character-
ized by hypophosphatemia, hypercalciuria, renal failure, disabling
bone deformities, osteomalcia, and myopathy [2, 7, 8]. As affected
individuals in our study family had neither signs nor symptoms
suggestive of clinically significant rickets or osteomalcia, we
hypothesize that the consequences of this voltage-gated chloride
channel mutation can be modified by other genes, diet, and/or
environment.
METHODS
Clinical evaluations
All studies were performed in accordance with the Brigham and
Women’s Hospital Human Research Committee quidelines for
the protection of human subjects from research risks. Forty-eight
family members (Fig. 1) were evaluated by medical histories,
physical examination, and serum chemistries (creatinine, blood
urea nitrogen, potassium, calcium, phosphate, alkaline phospha-
tase). Serum carbon dioxide, 1,25-vitamin D, and parathyroid
hormone levels were determined in selected individuals.
Twenty-four-hour urine calcium, creatinine, and protein excre-
tion was measured in 37 family members on an unrestricted diet
(I:3, II:1, II:6, II:8, II:10, II:11, II:15, II:17, II:19, II:21, II:23, II:26,
II:27, II:28, III:1, III:2, III:3, III:4, III:10, III:11 III:12, III:13,
III:14, III:16, III:17, III:18, III:19, III:20, III:21, III:22, III:23,
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III:24, III:25, III:26, III:27, IV:1, VI:2). In two individuals (II:10,
II:26) urine collections were inadequate. Twenty-four-hour urine
calcium and protein measurements obtained in 1974 were avail-
able for individuals I:1, I:3, I:5, I:7, I:9, II:1, II:13, II:24, II:25,
III:5, III:7, and III:8. Two individuals (III:12, III:13) had 24-hour
urine collections for calcium and beta2-microglobulin levels fol-
lowing an oral calcium challenge (calcium carbonate 1500 mg/
day 3 three days).
Beta2-microglobulin levels (indicating low molecular weight
proteins) were measured on random urine specimens from indi-
viduals II:6, II:8, II:27, II:28, III:5, III:6, III:8, III:9, III:12, III:13,
and III:20. Simultaneous urine pH measurements were also made,
as beta2-microglobulin is reportedly unstable in a urine pH less
than 5.5 [10]. Urinary citrate levels (which would be low in the
setting of renal tubular acidosis) were measured on selected
individuals (Tables 1 and 2).
Blood and urine studies were processed by Labcorp (formerly
National Health Laboratories Incorporated; Herndon, VA,
Family A
I.
II.
III.
IV.
Nephrolithiasis by history
Hypercalciuria by 24 hour urine
Renal insufficiency
Fig. 1. Pedigree structure of Family A.
Table 1. Clinical data, males with CLCN5 Ser244Leu mutation
Pedigree
number
Age
years
Serum chemistries Urine chemistries
Cr
mg/dl
CO2
mEq/liter
K
mEq/liter
Ca
mg/dl
Phos
mg/d1
Alk phos
U/liter Vit D/PTH
Ca
mg/kg
Ca
mg/24 hr
Protein
mg/24 hr pH
b2m
citrate/other
III:5 36 1.6 23 4.9 9.7 3.4 68 7.0 b2m-4.5
33 9.8 36.3c/36 116e b2m-3.1
nl-UPEP
32 7.2 3.4 9.2 5.9 Renal transplant
13 1.1 25 3.6 10.4 5.0 113 7.2 1827 5.5
10 1.1 23 4.5 10.8 4.7 23.5 2447 5.0
III:7 29 1.6 4.2 9.7 3.6 89
5 3.9 (83) 600
2 12.5 (163) 520 5.2
III:8b 27 2.1 26 3.3 10.0 2.4 90
26 2.2 23 3.1 10.2 2.0 84 b2m-20.5
4 0.3 23.5 3.9 10.4 4.0 312 10.4 690 5.7
II:13 47 Hemodialysis
25 1.9 25.5 4.2 9.4 3.0 94
22 1.6 27 4.0 3209 5.3
(231)a
III:27 13 10.3 58.4d/27 6.5 b2m-92.8
12 1.1 29 3.9 9.7 4.4 344 Citrate-0.430
11 1.0 30 3.4 9.7 6.4 314 6.8 (196) 819 Citrate-0.270
10 1.1 4.2 10.1 5.5 314 4.0 1103 6.3
3 0.6 22 4.8 10.1 342 4.9 (67) 7.5 Citrate-0.207
Abbreviations are: Cr, creatinine; Ca, calcium; Alk phos, alkaline phosphatase; Phos, Phosphates; Vit D, 1,25-vitamin D; PTH, parathyroid hormone;
b2m, beta2-microglobulin; nl, no abnormal bands; UPEP, urine protein electrophoresis.
a Low calcium diet (less than 300 mg/day)
b Taking potassium citrate 2000 mg/day
c 1,25-Vitamin D 12–40 pg/ml
d 1,25-Vitamin D 18–62 pg/ml
e urine aliquot; results based on 1 liter
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USA). Normal serum values for serum creatinine were: 0.3 to 0.8
mg/dl (ages 2 to 10 years), 0.3 to 1.0 mg/dl (ages 10 to 18 years),
0.6 to 1.5 mg/dl (over age 18 years). For phosphorus, the normal
serum values were: 2.5 to 6.5 mg/dl (ages 0 to 16 years), 2.5 to 4.5
mg/dl (over 17 years); and for alkaline phosphatase were: 80 to
490 U/liter (age 0 to 17 years), 25 to 140 U/liter (over 17 years).
Normal 24-hour calcium excretion was # 4.0 mg/kg. Normal urine
beta2-microglobulin levels were # 0.3 mg/liter. Normal 24-hour
urinary citrate levels 5 0.15–1.0 grams of citrate. Normal 1,25-
vitamin D levels were reported by National Health Laboratories
as 12 to 40 pg/ml (radioimmunoassay method). Normal 1,25
vitamin D levels were reported by Labcorp as 10 to 65 pg/ml
(column chromatography and radioimmunoassay methods). The
normal parathyroid hormone levels were reported as 10 to 65
pg/ml by both Labcorp and National Health Laboratories.
Individuals with renal failure were considered affected. Individ-
uals were classified as carriers either based on their clinical
presentation with hypercalciuria in combination with an elevated
urinary beta2-microglobulin level and a normal serum creatinine,
or because of their position in the pedigree.
Linkage analyses
DNA was isolated from five to thirty milliliters of peripheral
blood using the QIAamp (Qiagen) spin columns or from lympho-
blastoid lines [11] or following digestion with proteinase K and
phenol-chloroform purification [11]. Linkage between X-linked
renal failure and the proximal short arm of the X-chromosome
was assessed in all affected and unaffected family members over
age 10, using loci in the interval between DXS1003 and DXS106.
Genotypes were determined as described previously [11] and
LOD scores were calculated using the MLINK program, using
allele frequencies deduced from the unaffected spouses and a
penetrance of 80%.
Sequence analyses
Primers designed from intron sequences of the CLCN5 gene
[12] were used to amplify each exon using the polymerase chain
reaction (PCR). The products were gel-purified on a low melt gel
(1% agarose) and then recovered using a centrifuge tube filter
(0.22 um cellulose acetate in a 2.0 ml tube from Costar). Gel-
purified products were precipitated in alcohol, resuspended and
analyzed in cycle sequencing reactions using the Cyclist DNA
sequencing kit (Stratagene).
RESULTS
Clinical studies
Clinical evaluations in 48 family members identified 5 surviving
men (II:13, III:5, III:7, III:8, III:27) with renal insufficiency that
developed before age 30. Two individuals (II:13, III:5) had
end-stage renal failure. Individual II:13 underwent a renal trans-
plant at age 37 that failed after two years; he is currently on
Table 2. Clinical data, females with CLCN5 Ser244Leu mutation
Pedigree
number
Age
years
Serum chemistries Urine chemistries
Cr
mg/dl
Ca
mg/dl
Phos
mg/dl
Alk phos
U/liter 1,25-Vit D/PTH
Ca
mg/kg
Ca
mg/24 hr
Protein
mg/24 hr pH b2m-citrate/other
I:3 78 1.4 10.0 3.5 38 1.7 (144) 101
55 3.5 (316) 17
II:6 55 0.9 9.4 2.7 113 4.4 (400) 126e NA b2m-1.3
56 UPEP-nl
32 6.0 (390)
II:8 49 1.0 9.9 3.1 109
48 0.9 9.2 3.2 45.0c/31 42e NA b2m-2.8
UPEP-nl
47 0.7 9.6 6.4 91 3.47 (276) 335
25 0.6 9.9 2.8 128 9.0 (519)b
(161)a
II:28f 39 0.8 9.2 71 88.7d/28 5.1 b2m-1.3
36 0.9 9.7 6.4 (363) 53 8.0 Citrate-0.49
III:12 22 0.7 9.3 3.3 33 58.7d/21 5.0 b2m-2.0
20 5.6 (242)b 162 NA b2m-,1.0
19 0.8 10.3 5.5 38 2.5 (108) 41
III:13 13 0.6 10.1 4.8 167 74.5d/NA 7.0 b2m-8.3
11 5.0 (160)b 66
10 0.5 10.0 4.6 2.9 (91) 63
Abbreviations are: Cr, creatinine; Ca, calcium; Alk phos, alkaline phosphatase; Phos, phosphate; PTH, parathyroid hormone; b2m, beta2-
microglobulin; UPEP, urine protein electrophoresis; nl, no abnormal bands; NA, not available.
a Low calcium diet (less than 300 mg/day)
b High calcium diet
c 1,25-vitamin D, 12-40 pg/ml
d 1,25 Vit D 18–62 pg/ml
e Urine aliquot results calculated based on one liter
f Taking synthroid, birth control pills
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hemodialysis. Individual III:5 recently received a renal transplant
from his mother and is doing well. Two deceased male family
members (I:13, II:4) required hemodialysis in the third decade of
life.
Each affected male had a history of prolonged childhood
enuresis (persistent until age eight). Four affected individuals had
hypercalciuria that predated the onset of renal insufficiency
(Table 1). Urinary calcium excretion was not measured in Indi-
vidual II:13; a previous 24-hour urinary calcium measurement (on
a low calcium diet) was normal [1]. Four affected individuals
(II:13, III:5, III:7, III:8) had a history of multiple kidney stones
(10 to 20) first recognized during teenage years. Nephrocalcinosis,
diagnosed by either abdominal radiographs or renal ultrasound,
was noted in all four. X-ray and ultrasound studies have not shown
nephrocalcinosis in individual III:27, age 13 years.
All five affected males exhibited increased 24-hour protein
excretion prior to renal failure. A urine protein electrophoresis in
individual III:8 showed a total protein of 657 mg (urine aliquot,
results calculated based on one liter), albumin of 206 mg, and
globulin of 451 mg. Urine beta 2 microglobulin was 20.5 mg/liter.
Individual III:27 showed both tubular and glomerular proteinuria
at age 2. Urinary beta2-microglobulin were elevated in individuals
III:5, III:8, and III:27. (The significance of this elevation in
individual III:5 is unclear given his recent renal transplant.)
Six women (I:3, II:6, II:8, II:28, III:12, III:13) were identified as
carriers based on clinical examination and/or their location in the
family pedigree (Table 2). Five had persistent or intermittent
hypercalciuria and elevated urinary beta2-microglobulins. Individ-
ual I:3 had neither proteinuria nor hypercalciuria in 1974 nor
during this study (She currently takes multiple medications that
may alter urine chemistries.) A carrier status was assigned to her
based on her affected son (individual II:13). Serum creatinine,
blood urea nitrogen, potassium, phosphate, and alkaline phos-
phate levels were normal in all six women. Two individuals (III:12,
III:13) had a marked increase in 24-hour urine calcium excretion
(43% and 56%, respectively) after an oral calcium challenge
(Methods). A significant increase in urine calcium was also noted
in individual II:8 at age 25 on a high calcium diet [1]. 1,25-Vitamin
D levels were assessed in individuals II:8, II:28, III:12, and III:13
and were normal or mildly elevated. Parathyroid hormone levels
in each were normal.
Two women identified as carriers had renal stones. Individual
I:3 reported a history of several symptomatic renal stones at age
29. Asymptomatic bilateral nephrocalcinosis was recognized in
individual II:8 at age 25. She underwent a right nephrectomy at
age 47 for extensive renal calcium deposition, attributed, in part,
to a duplicated right renal pelvis. Pathologic examination of the
excised kidney revealed nonspecific changes with calcium deposits
in a few tubules.
Thirty-seven family members were considered unaffected. Six
unaffected women (I:7, I:9, II:24, III:22, III:23, IV:2) and 6
unaffected men (II:1, II:19, II:27, III:20, III:21, IV:1) had elevated
twenty-four-hour urinary calcium excretion during these or prior
(1974) clinical evaluations. Individuals IV:1 and IV:2 were receiv-
ing isoniazid for prophylaxsis against tuberculosis. Four unaf-
fected individuals (II:10, II:21, II:23, II:26) had had one or more
kidney stones. Urinary beta2-microglobulins were normal in II:27,
III:6, III:9, and III:20.
None of the affected males or carrier females in the present
study had metabolic acidosis. Ammonium chloride loading studies
published in 1974 [1] showed a defect in urine acidification with
normal serum bicarbonate in three affected males (individuals
II:4, III:5, III:8). They were considered to have incomplete renal
tubular acidosis [1]. Individual I:13 (now deceased) had a defect in
urine acidifcation and metabolic acidosis; the acidosis, however,
was likely due to end-stage renal failure. Normal serial urine
citrate levels have been demonstrated in individuals III:27 and
II:28.
Clinical evaluations and pedigree analysis of Family A demon-
strated an X-linked recessive phenotype. Affected men developed
renal insufficiency, whereas female carriers exhibited hypercalci-
uria and elevated urinary beta2-microglobulin levels. Isolated
hypercalciuria appeared to segregate as either a polygenic or
nonheritable trait.
Linkage analysis
Genetic studies were performed to assess linkage between the
X-linked trait in Family A and the proximal short arm of the X
chromosome where mutations in a voltage gated chloride channel
gene, CLCN5, have been demonstrated to cause XRN, Dent’s
disease, XLRH, and light weight proteinuria with hypercalciuric
nephrocalcinosis in Japanese males [2, 9]. Analyses with polymor-
phic loci (DXS1003, ARA, DXS426, DXS991, and DXS106)
demonstrated linkage to Xp11. A maximum LOD score of 3.75
was achieved with DXS426 (u5 0).
Sequence analysis
The protein encoding sequence of the candidate gene, CLCN5,
known to be in the interval defined by our linkage analysis, was
determined in two affected men from Family A. A C3T transi-
tion was identified in exon 6, which is predicted to replace the
normal serine (amino acid residue 244) with a leucine residue
(designated Ser244Leu; Fig. 2).
All five men with renal insufficiency (II:13, III:5, III:7, III:8,
III:27) carried the C3T transition in exon 6 of the CLCN5 gene.
Six carrier females were identified as being heterozygous for the
Ser244Leu mutation. In individuals I:3, II:6, II:8, and II:28 the
mutation was defined by sequence analysis. Individuals III:12 and
III:13 were defined as obligate carriers of the mutation by their
position in the pedigree (affected father). Family members with
isolated hypercalciuria or normal clinical studies did not have the
Ser244Leu mutation.
Genotype/phenotype correlates
A previous report demonstrated that the Ser244Leu mutation
in CLCN5 caused X-linked recessive hypophosphatemic rickets in
one family [2]. To determine whether clinically significant rickets
was present in affected individuals in Family A, relevant clinical
histories, laboratory values, and radiographs were reviewed. No
men nor women with the Ser244Leu mutation had bone pain,
bone deformity, frequent fractures, short stature, or myopathy.
Analyses of serum chemistries in men and women with the
CLCN5 Ser244Leu mutation demonstrated normal calcium, alka-
line phosphate, and phosphate levels in all individuals with the
CLCN5 Ser244Leu mutation except for individual III:8 who had a
decreased phosphate level.
Twenty-four-hour urine collections done in 1974 showed nor-
mal tubular reabsorption of phosphate in affected individuals [1].
Elevations of alkaline phosphatase were reported in 1974 for
Individuals I:5 and II:8. Their current studies are normal. Radio-
graphs obtained from individuals II:8, III:5, III:7, III:8, and III:27
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did not show evidence of old fractures, pseudofractures nor other
bony abnormalities.
DISCUSSION
We demonstrate that a missense (Ser244Leu) mutation in the
CLCN5 gene, previously identified as the molecular etiology of
X-linked recessive hypophosphatemic rickets, causes renal failure
without clinically significant rickets or osteomalcia in Family A.
Both female carriers and affected men exhibited hypercalciuria
and low molecular weight proteinuria, but only men developed
progressive renal insufficiency and ultimately renal failure.
Previous studies on X-linked recessive hypophoshatemic rickets
caused by the Ser244Leu mutation in CLCN5 reported disabling
bone deformities, osteomalcia, and myopathy [2, 7, 8]. Affected
men in Family A did not exhibit these abnormalities. Although we
did not perform iliac crest biopsies, none of the stigmata of biopsy
proven osteomalcia such as a low serum calcium, low serum
phosphate, elevated alkaline phosphate, or abnormal x-rays [13]
were present in affected individuals in Family A (except for
individual III:8 where one low serum phosphate level was noted).
We conclude that the Ser244Leu mutation can occur without
clinically significant bone disease.
Hypercalciuria and nephrolithiasis, whether occurring alone or
in combination, had a poor predictive value in identifying individ-
uals at risk for developing renal insufficiency. Hypercalciuira was
found in 12 individuals in Family A with a normal CLCN5
sequence. Although hypercalciuria is estimated to occur in ap-
proximately 2% to 4% of normal individuals [14], 32% of unaf-
fected Family A members exhibited this finding. The incidence of
nephrolithiasis was similarly higher than that reported for the
general population where 0.5% of otherwise normal individuals
experience renal stones [14]. Five unaffected individuals and four
unrelated spouses of Family A had a history of one to three renal
stones occurring after age 20. However, individuals with the
Ser244Leu mutation in CLCN5 reported multiple renal stones
that presented during the teenage years.
Elevated levels of urine beta2-microglobulin were present in the
three affected males and five female carriers in whom it was
measured. Heterozygous women had mild elevations whereas
affected men exhibited more marked elevations. Urinary levels of
this low molecular weight protein also discriminated between
isolated hypercalciuria and hypercalciuria accompanied by renal
insufficiency. For example, hypercalciuria occurred in individual
III:20. However, urine beta2-microglobulin levels were normal
and he had no evidence of renal insufficiency.
The missense mutation Ser244Leu is likely to significantly alter
the function of the CLCN5 channel. CLCN5 is one of at least
seven mammalian voltage gated chloride channel genes identified
and shows 78% amino acid homology to two other chloride
channels, CLC-3 and CLC-4 [12, 15, 16]. In rats, CLCN5 appears
to be expressed significantly in all segments of the renal tubule
except the glomerulus and the S2 segment of the proximal tubule
[16]. Its subcellular localization remains unknown. Residue 244 is
located in a transmembrane domain of the channel, where
substitution of a leucine for the normally encoded serine might
perturb the alpha helical structure of this domain. In vitro
expression of Ser244Leu CLCN5 mutation in oocytes have dem-
onstrated that the chloride currents are significantly diminished,
whereas in other mutations the currents are abolished, suggesting
that the gene defect can act functionally as a null allele [2].
Although the cellular consequences of a mutated CLCN5
channel are unknown, we hypothesize that this defect alters renal
reabsorption of low molecular weight proteins (LMWP), resulting
in renal failure via a mechanism analogous to the development of
chronic pancreatitis in cystic fibrosis. The cystic fibrosis transmem-
brane conductance regulator (CFTR) is located in the apical
plasma membrane (APM) of pancreatic acinar cells in the pan-
creas [17]. The CFTR maintains an alkaline environment which is
critical for cleavage of GP2, a glycosyl phosphatidyl-inositol (GPI)
anchored protein that regulates endocytosis at the apical plasma
membrane [18–21]. Acidification fosters GP2 anchoring to the
apical membrane, GP2 precipitation, and ultimately pancreatic
duct blockage and dilation.
GP2 shows significant amino acid homology to the Tamm-
Horsfall protein (THP or uromodulin) [22], a member of the
family of glycosyl phosphatidyl-inositol anchored proteins in the
kidney. Data showing comparative sequence analysis as well as
conserved domain structure suggest functional homology [23]. We
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Fig. 2. Detection of C3T missense mutation in CLCN5. Normal sequence (left) is from an unaffected individual. Affected individuals (right) had a
C3T mutation at residue 244 that replaces the normal serine with leucine in domain 5 of CLCN5.
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hypothesize that THP or a related protein has functions compa-
rable to the GP2 protein. Immunogold labeling of THP in rats
localized this protein both in the apical cytoplasm and in vesicles
fused with APM making them a candidate for the endocytosis of
LMWP [24]. Although these vesicles have been localized primar-
ily to the tall ascending loop of Henle, THP has been found in the
proximal tubule and glomerulus in renal pathologies [25]. If
CLCN5 regulates pH in either the tubular lumen or endosome
and fosters THP-mediated (or related proteins) endocytosis of
LMWP, CLCN5 mutations might alter tubular pH and prevent
endocytosis of LMWP. Tubular precipitation of protein might
result in obstruction and dilation; both would further impair
tubular function and create a nidus for additional calcium precip-
itation and stone formation.
All disorders associated with CLCN5 mutations have features
similar to those observed in Family A, including hypercalciuria,
low molecular weight proteinuria, nephrocalcinosis, and nephro-
lithiasis. Renal failure, the defining feature in Family A, was not
observed in Japanese children (which likely reflects the young age
of the study population), but was relatively common in men with
these other disorders (9 of 14 in patients over age 10 with Dent’s
disease [5], 4 of 8 with XRN [3], and 3 of 5 with XLRH [7, 8].
Hypophosphatemia, the defining feature in XLRH, is relatively
common in males with Dent’s disease (6 of 15) [5], and XRN (3
of 6) [3], but rare in family A. In serum studies performed in
Family A over a twenty year period, only one individual was
reported to have hypophosphatemia on one of three occasions
(III:8, Table 1) and none had clinical evidence of osteomalcia.
Thus, of all the disorders reported with mutations in CLCN5,
Family A least resembles phenotypically the family previously
reported with the same Ser244Leu mutation. The present study,
therefore, underscores the varied manifestations that may be
associated with mutations in the CLCN5 gene and the importance
of renal failure. Whether these phenotypic variations reflect
environmental differences, diet, and/or modifying genetic back-
grounds remains to be determined. The similarities between these
five clinical syndromes and the finding that the same mutation
causes two distinct clinical syndromes suggests that all these
conditions may be varied manifestations of the same disease
process. Definition of the cellular consequences that CLCN5
mutations have on renal tubular physiology should help elucidate
the mechanisms by which clinical syndromes result from a com-
mon gene defect, and may explain how renal failure developes in
these and possibly other renal pathologies.
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APPENDIX
Abbreviations used in this article are: XRN, X-linked recessive neph-
rolithiasis; XLRH, X-linked hypophosphatemic rickets; PCR, polymerase
chain reaction; CLCN5, chloride channel gene; CFTR, cystic fibrosis
transmembrane conductance regulator; LMWP, low molecular weight
proteins; APM, apical plasma membrane; GPI, glycosyl phosphatidyl-
inositol; THP, Tamm-Horsfall protein.
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